Corporate Profile

Onconetix, Inc. (Nasdaq: ONCO) (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. For more information, visit www.onconetix.com.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Events

SEC Filings

Quarterly report which provides a continuing view of a company's financial position

10-Q

Notification that form type 10-Q will be submitted late

NT 10-Q

Report of unscheduled material events or corporate event

8-K